Summary

Orthobiologics Market – Scope of Report
TMR’s report on the global orthobiologics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global orthobiologics market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global orthobiologics market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the orthobiologics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global orthobiologics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global orthobiologics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global orthobiologics market.

The report delves into the competitive landscape of the global orthobiologics market. Key players operating in the global orthobiologics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global orthobiologics market profiled in this report.

Key Questions Answered in Global orthobiologics Market Report
• What is the sales/revenue generated by orthobiologics across all regions during the forecast period?
• What are the opportunities in the global orthobiologics market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Orthobiologics Market – Research Objectives and Research Approach
The comprehensive report on the global orthobiologics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global orthobiologics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global orthobiologics market.

ページTOPに戻る

Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Orthobiologics Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Orthobiologics Market Analysis and Forecasts, 2017-2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Technological Advancements in Orthobiologics
5.2. Incidence of Orthopedic Disorders
5.3. Regulatory Scenario, by Key Countries
5.4. Reimbursement Scenario, by Key Countries
5.5. Pricing Analysis of Orthobiologics
5.6. Pipeline Analysis
5.7. Overview of Most Effective Combinations of Orthobiologics products
5.8. COVID-19 Pandemic Impact Analysis
6. Global Orthobiologics Market Analysis and Forecasts, By Product
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Product, 2017-2031
6.3.1. Demineralized Bone Matrix (DBM)
6.3.2. Hydroxyapatite (HAp)
6.3.3. Hyaluronic acid (HA)
6.3.4. Calcium Sulfate Matrix
6.3.5. β-tricalcium phosphate (β-TCP)
6.3.6. β-TCP + HAp
6.3.7. DBM + PLGA
6.3.8. Regenerative Medicine
6.3.8.1. PRP
6.3.8.2. BMAC
6.3.8.3. SVF
6.3.8.4. Others (Exosome, etc.)
6.3.9. Growth Factors
6.3.9.1. BMP2
6.3.9.2. FGF2
6.3.9.3. TGF beta
6.3.9.4. VEGF
6.3.9.5. Others (IGF, etc.)
6.4. Market Attractiveness By Product
7. Global Orthobiologics Market Analysis and Forecasts, By End-user
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By End-user, 2017-2031
7.3.1. Hospitals
7.3.2. Orthopedic Clinics
7.3.3. Others (ENT Clinics, etc.)
7.4. Market Attractiveness By End-user
8. Global Orthobiologics Market Analysis and Forecasts, By Region
8.1. Key Findings
8.2. Market Value Forecast By Region
8.2.1. Europe
8.2.2. India
8.2.3. Rest of the World
8.3. Market Attractiveness By Country/Region
9. Europe Orthobiologics Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast By Product, 2017-2031
9.2.1. Demineralized Bone Matrix (DBM)
9.2.2. Hydroxyapatite (HAp)
9.2.3. Hyaluronic acid (HA)
9.2.4. Calcium Sulfate Matrix
9.2.5. β-tricalcium phosphate (β-TCP)
9.2.6. β-TCP + Hap
9.2.7. DBM + PLGA
9.2.8. β-TCP + PLGA
9.2.9. Regenerative Medicine
9.2.9.1. PRP
9.2.9.2. BMAC
9.2.9.3. SVF
9.2.9.4. Others (Exosome, etc.)
9.2.10. Growth Factors
9.2.10.1. BMP2
9.2.10.2. FGF2
9.2.10.3. TGF beta
9.2.10.4. VEGF
9.2.10.5. Others (IGF, etc.)
9.3. Market Value Forecast By End-user, 2017-2031
9.3.1. Hospitals
9.3.2. Orthopedic Clinics
9.3.3. Others (ENT Clinics, etc.)
9.4. Market Value Forecast By Country, 2017-2031
9.4.1. Germany
9.4.2. U.K.
9.4.3. France
9.4.4. Italy
9.4.5. Spain
9.4.6. Rest of Europe
9.5. Market Attractiveness Analysis
9.5.1. By Product
9.5.2. By End-user
9.5.3. By Country
10. India Orthobiologics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast By Product, 2017-2031
10.2.1. Demineralized Bone Matrix (DBM)
10.2.2. Hydroxyapatite (HAp)
10.2.3. Hyaluronic acid (HA)
10.2.4. Calcium Sulfate Matrix
10.2.5. β-tricalcium phosphate (β-TCP)
10.2.6. β-TCP + HAp
10.2.7. DBM + PLGA
10.2.8. β-TCP + PLGA
10.2.9. Regenerative Medicine
10.2.9.1. PRP
10.2.9.2. BMAC
10.2.9.3. SVF
10.2.9.4. Others (Exosome, etc.)
10.2.10. Growth Factors
10.2.10.1. BMP2
10.2.10.2. FGF2
10.2.10.3. TGF beta
10.2.10.4. VEGF
10.2.10.5. Others (IGF, etc.)
10.3. Market Value Forecast By End-user, 2017-2031
10.3.1. Hospitals
10.3.2. Orthopedic Clinics
10.3.3. Others (ENT Clinics, etc.)
10.4. Market Attractiveness Analysis
10.4.1. By Product
10.4.2. By End-user
11. Rest of the World Orthobiologics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast By Product, 2017-2031
11.2.1. Demineralized Bone Matrix (DBM)
11.2.2. Hydroxyapatite (HAp)
11.2.3. Hyaluronic acid (HA)
11.2.4. Calcium Sulfate Matrix
11.2.5. β-tricalcium phosphate (β-TCP)
11.2.6. β-TCP + HAp
11.2.7. DBM + PLGA
11.2.8. β-TCP + PLGA
11.2.9. Regenerative Medicine
11.2.9.1. PRP
11.2.9.2. BMAC
11.2.9.3. SVF
11.2.9.4. Others (Exosome, etc.)
11.2.10. Growth Factors
11.2.10.1. BMP2
11.2.10.2. FGF2
11.2.10.3. TGF beta
11.2.10.4. VEGF
11.2.10.5. Others (IGF, etc.)
11.3. Market Value Forecast By End-user, 2017-2031
11.3.1. Hospitals
11.3.2. Orthopedic Clinics
11.3.3. Others (ENT Clinics, etc.)
11.4. Market Attractiveness Analysis
11.4.1. By Product
11.4.2. By End-user
12. Competition Landscape
12.1. Market Player - Competition Matrix (By Tier and Size of companies)
12.2. Market Share Analysis By Company (2022)
12.3. Company Profiles
12.3.1. Arthrex, Inc.
12.3.1.1. Company Overview
12.3.1.2. Financial Overview
12.3.1.3. Product Portfolio
12.3.1.4. Business Strategies
12.3.1.5. Recent Developments
12.3.2. ATEC Spine, Inc.
12.3.2.1. Company Overview
12.3.2.2. Financial Overview
12.3.2.3. Product Portfolio
12.3.2.4. Business Strategies
12.3.2.5. Recent Developments
12.3.3. Bioventus
12.3.3.1. Company Overview
12.3.3.2. Financial Overview
12.3.3.3. Product Portfolio
12.3.3.4. Business Strategies
12.3.3.5. Recent Developments
12.3.4. Exactech, Inc.
12.3.4.1. Company Overview
12.3.4.2. Financial Overview
12.3.4.3. Product Portfolio
12.3.4.4. Business Strategies
12.3.4.5. Recent Developments
12.3.5. Globus Medical
12.3.5.1. Company Overview
12.3.5.2. Financial Overview
12.3.5.3. Product Portfolio
12.3.5.4. Business Strategies
12.3.5.5. Recent Developments
12.3.6. Integra Lifesciences Corporation
12.3.6.1. Company Overview
12.3.6.2. Financial Overview
12.3.6.3. Product Portfolio
12.3.6.4. Business Strategies
12.3.6.5. Recent Developments
12.3.7. Johnson & Johnson
12.3.7.1. Company Overview
12.3.7.2. Financial Overview
12.3.7.3. Product Portfolio
12.3.7.4. Business Strategies
12.3.7.5. Recent Developments
12.3.8. Medtronic plc
12.3.8.1. Company Overview
12.3.8.2. Financial Overview
12.3.8.3. Product Portfolio
12.3.8.4. Business Strategies
12.3.8.5. Recent Developments
12.3.9. MTF Biologics
12.3.9.1. Company Overview
12.3.9.2. Financial Overview
12.3.9.3. Product Portfolio
12.3.9.4. Business Strategies
12.3.9.5. Recent Developments
12.3.10. NORAKER
12.3.10.1. Company Overview
12.3.10.2. Financial Overview
12.3.10.3. Product Portfolio
12.3.10.4. Business Strategies
12.3.10.5. Recent Developments
12.3.11. RTI Surgical
12.3.11.1. Company Overview
12.3.11.2. Financial Overview
12.3.11.3. Product Portfolio
12.3.11.4. Business Strategies
12.3.11.5. Recent Developments
12.3.12. Stryker
12.3.12.1. Company Overview
12.3.12.2. Financial Overview
12.3.12.3. Product Portfolio
12.3.12.4. Business Strategies
12.3.12.5. Recent Developments
12.3.13. Zimmer Biomet
12.3.13.1. Company Overview
12.3.13.2. Financial Overview
12.3.13.3. Product Portfolio
12.3.13.4. Business Strategies
12.3.13.5. Recent Developments